title: [Effect of different combined antihypertensive regimen on the erectile function in male hypertensive patients].
abstract: OBJECTIVE
  To compare the effects of felodipine combined irbesartan regimen with that of felodipine combined metoprolol regimen on the sexual function in male hypertensive patients.
  
  
  METHODS
  One hundred and twenty-three male hypertensive patients (age 25 to 60) were randomly assigned to felodipine (5 mg/d) plus irbesartan (150 mg/d, n = 64) group and felodipine (5 mg/d) plus metoprolol (47.5 mg/d, n = 59) group. Dosage of felodipine were doubled after 4 weeks if the blood pressure were > or = 140/ 90 mm Hg (1 mm Hg = 0.133 kPa). At the baseline and post 24th week treatment, sexual function of patients was assessed by the International Index of Erectile Function (IIEF) Questionaire. Serum testosterone (T), sex hormone binding globulin (SHBG), 4-hydroxynonenal (HNE), 8-hydroxy-2'-deoxyguanosine (8-OHdG) and Malonaldehyde (MDA) were measured by Radioimmunoassay (RIA), ELISA and TBA respectively.
  
  
  RESULTS
  Total prevalence of erectile dysfunction (ED), T, SHBG and HNE were similar between pre- and post-treatment in two groups (P > 0.05). On the other hand, the scores of the mild ED and sexual desire (SD) were improved and both serum 8-OHdG and MDA in patients with ED decreased [(146.02 +/- 60.54) ng/L vs. (139.89 +/- 62.03) ng/L, P = 0.048 and (6.59 +/- 1.75) micromol/L vs. (5.51 +/- 1.65) micromol/L, P = 0.039] in Felodipine plus Irbesartan group.
  
  
  CONCLUSIONS
  The results suggested that Felodipine + Irbesartan regimen may be superior to Felodipine + metoprolol regimen for male hypertensive patients with mild ED.
authors.affiliation: Department of Cardiology, Second Hospital of Lanzhou University, Lanzhou 730030, China.
authors.forename: Long-Quan
authors.initials: LQ
authors.lastname: Yang
authors.forename: Jing
authors.initials: J
authors.lastname: Yu
authors.forename: Rui-Xin
authors.initials: RX
authors.lastname: Ma
authors.forename: Pei-Jun
authors.initials: PJ
authors.lastname: Liu
authors.forename: Xue-Ya
authors.initials: XY
authors.lastname: Guo
authors.forename: Xiu-Li
authors.initials: XL
authors.lastname: Li
authors.forename: Peng
authors.initials: P
authors.lastname: Chang
authors.forename: Hao
authors.initials: H
authors.lastname: Hu
authors.forename: Feng
authors.initials: F
authors.lastname: Zhao
authors.forename: Feng
authors.initials: F
authors.lastname: Bai
mesh_terms: D000328:Adult; D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001713:Biphenyl Compounds / Q000008:administration & dosage / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D007172:Erectile Dysfunction / Q000139:chemically induced* / Q000503:physiopathology; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000503:physiopathology; D000077405:Irbesartan; D008297:Male; D008790:Metoprolol / Q000008:administration & dosage / Q000627:therapeutic use*; D008875:Middle Aged; D010410:Penile Erection / Q000187:drug effects*; D013777:Tetrazoles / Q000008:administration & dosage / Q000627:therapeutic use*
chemical_list: D000959:Antihypertensive Agents; D001713:Biphenyl Compounds; D013777:Tetrazoles; D008790:Metoprolol; D000077405:Irbesartan